Arvaya Healthcare board approved a material related-party transaction to acquire an intellectual property portfolio for up to ₹10 crore. The deal involves DEFIB Institute of Health Solutions LLP and will be funded from rights issue proceeds.

The Board of Directors met on August 26, 2026, to consider the acquisition of the copyright and IP portfolio of DEFIB Institute of Health Solutions LLP (LLPIN: AAS-7091). The transaction is structured strictly as an assignment of identified intellectual property assets, copyrights, and associated rights. It does not involve a slump sale or the acquisition of the entire business undertaking of the LLP.

Transaction Structure and Funding

The total consideration for the acquisition shall not exceed ₹10 crore, based on an independent valuation of the identified IP assets. The company proposed funding this consideration out of the proceeds from its Rights Issue. This funding method is subject to compliance with applicable provisions and the objects specified in the Rights Issue documents.

Regulatory Compliance and Governance

Being classified as a Material Related Party Transaction, the proposal requires adherence to the Companies Act, 2013, and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This includes obtaining shareholder approval if applicable.

The Audit Committee reviewed and recommended the draft Copyright & IP Assignment Agreement, valuation report, and material terms prior to the Board’s approval. The Board revised the scope and structure of the proposed transaction during the meeting, shifting from a broader business undertaking acquisition to a specific IP portfolio purchase.

What the Numbers Show

The decision to fund the ₹10 crore IP acquisition specifically through Rights Issue proceeds indicates a strategic alignment between capital raising and asset deployment. By restricting the transaction to identified IP assets rather than a full slump sale, the company isolates the acquisition to specific intellectual property rights, potentially limiting exposure to legacy liabilities associated with the target LLP’s broader operations.

Arvaya Healthcare Limited has scheduled a Board of Directors meeting for August 26, 2026, to consider the acquisition of the business undertaking of Navahmedi Solution Private Limited. The proposed transaction involves a slump sale covering intellectual property, assets, and liabilities.

The company intends to fund this related party transaction using proceeds from its rights issue. This strategic move aims to expand Arvaya’s operational footprint through asset acquisition rather than organic growth in the immediate term.

Transaction Details

The board agenda specifically includes the approval of the related party transaction with Navahmedi Solution Private Limited. The structure of the deal is defined as a slump sale, which allows for the transfer of the entire business unit as a going concern.

Regulatory Compliance

Arvaya Healthcare Limited issued this intimation pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was filed with the Bombay Stock Exchange Listing Department on August 21, 2026.

Kaushal Shah, Managing Director of the company, signed the intimation. The company, formerly known as Bijoy Hans Limited, operates under ISIN INE491D01017.